Given the importance of wild-type p53 for the MDM2 mechanism of action, it is not surprising that the MDM2 inhibitor AMG 232, now called KRT-232, was tested in p53 wild-type multiple myeloma and solid tumors and specifically excluded del(17p) multiple myeloma (139). The gene discussed is TP53; the disease is plasma cell myeloma.